The IP Development Incentive can drop your tax on IP income to 5% or 10%, and section 19B lets you write down acquisition cost against future royalties. The catch — and it matters — is that IDI uses the OECD modified nexus approach, so the rate is proportional to how much R&D you actually do in Singapore. We've structured enough IP migrations to know which ones survive parent-country exit taxation and which don't. We'll model both sides before you commit.
How we get IP into the SG entity — and how the licence flows back out — depends on whether you're moving existing IP from elsewhere or starting fresh. Each has different exit-tax, transfer-pricing, and modified-nexus implications. We'll work through the right shape on the first call.
IP is transferred from a group entity (often a US or EU parent) to the SG entity at fair market value. The SG entity claims section 19B capital allowance on the acquisition cost and licences the IP back out to operating subs at arm’s length. Requires careful transfer-pricing documentation on the original sale and ongoing licence; the originating jurisdiction usually has exit-tax implications worth modelling before the move.
IP is developed in Singapore from day one, typically by SG-based engineering or R&D headcount. The SG entity owns the IP from creation, and qualifying R&D spend feeds directly into the modified nexus ratio used by IDI. Cleanest path from an OECD-compliance standpoint, but slower to scale.
The SG entity participates in a group cost-sharing arrangement with related entities (e.g. US parent doing core R&D, SG sub doing regional adaptation). SG holds the rights to commercialise the IP in defined territories. Common in software groups where the trunk of R&D is in the US but the EU/Asia revenue is layered through SG.
IDI is the headline incentive but the underlying section 19B mechanism and the broader corporate tax regime do most of the heavy lifting. The full benefit comes from stacking them correctly.
Companies undertaking IP development activities in Singapore with qualifying R&D expenditure, structured around the OECD modified nexus approach.
Concessionary corporate tax rate of 5% or 10% on income from qualifying IP, proportional to qualifying R&D performed in Singapore.
Modified nexus ratio limits the concessionary rate to (qualifying R&D × 1.3) ÷ (total IP-related spend). Outsourced R&D to related parties reduces the ratio.
Companies acquiring qualifying intellectual property rights (patents, copyrights, trade marks, registered designs, etc.) for use in their trade or business.
Up to 100% writing-down allowance on the acquisition cost, claimable over a 5 / 10 / 15-year period.
Trade marks are excluded from s.19B from YA 2026 onwards (transitional rules apply for marks acquired before then).
Companies undertaking qualifying R&D in Singapore.
100% deduction on qualifying R&D expenditure plus enhanced 50–100% additional deduction on the first SGD 400k of qualifying expenditure under the Enterprise Innovation Scheme (YA 2024–2028).
Singapore acquirers of qualifying IP via M&A.
25% allowance on acquisition cost (up to SGD 10m per YA) plus DST waiver. Stacks with s.19B.
Almost certainly, yes. Most developed jurisdictions impose exit / transfer-of-functions taxation when valuable IP migrates to a low-tax jurisdiction. The deemed sale is at fair market value, taxed at the originating country’s normal corporate rate. We model this before any migration — sometimes the answer is "stage the migration over 3–5 years using a cost-sharing arrangement," sometimes it’s "develop new IP in SG and leave the legacy IP where it is."
IDI’s nexus ratio is: (qualifying R&D expenditure × 1.3) divided by (qualifying R&D + acquisition costs + outsourced R&D to related parties), capped at 1. The concessionary rate applies only to the portion of IP income that matches this ratio — the rest is taxed at the standard 17%. The "uplift" of 1.3x rewards substantive R&D done in Singapore, and outsourcing R&D to related parties dilutes the ratio. We track the ratio annually as part of close.
Less so after the 2026 changes to s.19B. Trade marks are still acquirable in SG and royalty income on trade marks is taxed under the normal corporate regime, but the capital allowance benefit is going away. For groups focused on trade mark IP, Singapore is still competitive on substance and treaty grounds but the case is more marginal vs Hong Kong or other jurisdictions.
Yes. IDI is a substance-based incentive and the modified nexus ratio rewards R&D performed by qualifying personnel in Singapore. We typically see successful IDI applicants with 8–25 SG-based engineering / R&D headcount as a starting point, growing with the IP portfolio. Pure IP-holding setups without operating R&D rarely get IDI; they pay 17% on royalty income, which is still competitive but not the headline benefit.
Royalties received by the SG entity are taxed at the corporate rate (17% standard, or the IDI concessionary rate if approved). Most ASEAN treaties give Singapore-recipient royalties a 5–10% WHT reduction at source (vs the 15–25% domestic rates). The WHT paid at source is creditable against Singapore tax on the same income, so the effective burden is the higher of the two rates.
A real concern for US, UK, EU, Australian, and Canadian parents in particular. CFC / Subpart F / GILTI / hybrid mismatch rules can pull SG IP income back into the parent jurisdiction even if SG has full substance. We typically work with the group’s tax adviser in the parent country to model the CFC implications before any IP structure is finalised.
Our Singapore team handles incorporation, bank account introduction, and ongoing compliance under one project manager. Same point of contact from the first call through the second annual return.